Quantitative analysis of a panel of gene expression in prostate cancer—with emphasis on NPY expression analysis

ObjectiveTo investigate molecular alterations associating with prostate carcinoma progression and potentially provide information toward more accurate prognosis/diagnosis.MethodsA set of laser captured microdissected (LCM) specimens from 300 prostate cancer (PCa) patients undergoing radical prostatectomy (RP) were defined. Ten patients representing “aggressive” PCa, and 10 representing “non-aggressive” PCa were selected based on prostate-specific antigen (PSA) recurrence, Gleason score, pathological stage and tumor cell differentiation, with matched patient age and race between the two groups. Normal and neoplastic prostate epithelial cells were collected with LCM from frozen tissue slides obtained from the RP specimens. The expressions of a panel of genes, including NPY, PTEN, AR, AMACR, DD3, and GSTP1, were measured by quantitative real-time RT-PCR (TaqMan), and correlation was analyzed with clinicopathological features.ResultsThe expressions of AMACR and DD3 were consistently up-regulated in cancer cells compared to benign prostate epithelial cells in all PCa patients, whereas GSTP1 expression was down regulated in each patient. NPY, PTEN and AR exhibited a striking difference in their expression patterns between aggressive and non-aggressive PCas (P=0.0203, 0.0284, and 0.0378, respectively, Wilcoxon rank sum test). The lower expression of NPY showed association with “aggressive” PCas based on a larger PCa patient cohort analysis (P=0.0037, univariate generalized linear model (GLM) analysis).ConclusionDespite widely noted heterogeneous nature of PCa, gene expression alterations of AMACR, DD3, and GSTP1 in LCM-derived PCa epithelial cells suggest for common underlying mechanisms in the initiation of PCa. Lower NPY expression level is significantly associated with more aggressive clinical behavior of PCa; PTEN and AR may have potential in defining PCa with aggressive clinical behavior. Studies along these lines have potential to define PCa-associated gene expression alterations and likely co-regulation of genes/pathways critical in the biology of PCa onset/progression.

[1]  B. Loftus,et al.  Heterogeneous expression of α‐methylacyl‐CoA racemase in prostatic cancer correlates with Gleason score , 2007, Histopathology.

[2]  J. Squire,et al.  FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome , 2007, British Journal of Cancer.

[3]  H. Razvi,et al.  Expression of human telomerase reverse transcriptase, Survivin, DD3 and PCGEM1 messenger RNA in archival prostate carcinoma tissue. , 2006, The Canadian journal of urology.

[4]  E. Lander,et al.  Gene expression correlates of clinical prostate cancer behavior. , 2002, Cancer cell.

[5]  Gordon Broderick,et al.  Gene Expression Correlates of Unexplained Fatigue , 2006, Pharmacogenomics.

[6]  J C Reubi,et al.  Y(1)-mediated effect of neuropeptide Y in cancer: breast carcinomas as targets. , 2001, Cancer research.

[7]  O. Dietze,et al.  Vasoactive intestinal polypeptide (VIP) and neuropeptide tyrosine (NPY) in prostate carcinoma. , 1997, European journal of cancer.

[8]  S. Said Vasoactive Intestinal Polypeptide (VIP) in Asthma a , 1991, Annals of the New York Academy of Sciences.

[9]  R. Montironi,et al.  Carcinoma of the prostate: inherited susceptibility, somatic gene defects and androgen receptors , 2004, Virchows Archiv.

[10]  J. Kench,et al.  Aberrant Neuropeptide Y and Macrophage Inhibitory Cytokine-1 Expression Are Early Events in Prostate Cancer Development and Are Associated with Poor Prognosis , 2006, Cancer Epidemiology Biomarkers & Prevention.

[11]  A. D'Amico,et al.  Combined-modality staging for localized adenocarcinoma of the prostate. , 2001, Oncology.

[12]  A. Ziaee,et al.  Role of PTEN gene in progression of prostate cancer. , 2007, Urology journal.

[13]  Beatrice Gralton,et al.  Washington DC - USA , 2008 .

[14]  P. Magni,et al.  Modulatory actions of neuropeptide Y on prostate cancer growth: role of MAP kinase/ERK 1/2 activation. , 2007, Advances in experimental medicine and biology.

[15]  C. Cavadas,et al.  Neuropeptide Y and its receptors as potential therapeutic drug targets. , 2002, Clinica chimica acta; international journal of clinical chemistry.

[16]  Arul M Chinnaiyan,et al.  Molecular markers to identify patients at risk for recurrence after primary treatment for prostate cancer. , 2003, Urology.

[17]  Paolo Magni,et al.  Activation of the Y1 receptor by neuropeptide Y regulates the growth of prostate cancer cells. , 2006, Endocrinology.

[18]  D. Bostwick,et al.  Glutathione S-transferase pi (GSTP1) hypermethylation in prostate cancer: review 2007. , 2007, Pathology.

[19]  H. Jörnvall,et al.  Limited neuropeptide Y precursor processing in unfavourable metastatic neuroblastoma tumours , 2000, British Journal of Cancer.

[20]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[21]  R. Fahlbusch,et al.  Gene expression of adrenomedullin, leptin, their receptors and neuropeptide Y in hormone‐secreting and non‐functioning pituitary adenomas, meningiomas and malignant intracranial tumours in humans , 2001, Neuropathology and applied neurobiology.

[22]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.